Background The benefit of pharmacogenetic testing before starting drug therapy has been
well documented for several single gene–drug combinations. However, the clinical utility of …

The impact of body mass index (BMI) on treatment outcomes in patients with cancer is
gaining increasing attention given the limited data available. The aim of this study was to …

Mast cells (MCs) are a potent proangiogenic factor in tumors, they product several pro-
angiogenic factors such as fibroblast growth factor 2 (FGF-2), vascular epithelial growth …

Background Adding immunotherapy to first-line chemotherapy might improve outcomes for
patients with advanced or recurrent endometrial cancer. We aimed to compare carboplatin …

Poly (ADP-ribose) polymerase inhibitors (PARPis) are becoming increasingly meaningful in
oncology, and their therapeutic drug monitoring (TDM) might be beneficial for patients …

Background Invasive vulvar Paget's disease with over-expression of the human epidermal
growth factor receptor 2 (HER2) protein is potentially suitable for targeted therapy, especially …

A wide interindividual variability in therapeutic response to cyclin-dependent kinases 4 and
6 inhibitors (CDKis) palbociclib, ribociclib and abemaciclib, among patients with HR+/HER2 …

Until recently, effective therapies for advanced endometrial cancer progressing to a platinum-
based combination were lacking. In this setting, immunotherapy with anti PD-1/PDL-1 …

Background: It was the aim of this study to evaluate the efficacy of docetaxel and vinorelbine
combination in well-defined anthracycline-'exposed'or-'resistant'advanced breast cancer …

The aim of this study was to evaluate activity and tolerability of docetaxel-gemcitabine
combination as first-line treatment in patients with metastatic breast cancer previously …